Background: The effect of histology-based treatment regimen on diffuse gastric adenocarcinoma has not been evaluated in clinical trials. This international phase III trial evaluated the efficacy and safety of S-1 (a contemporary oral fluoropyrimidine)/cisplatin versus 5-fluorouracil (5-FU)/cisplatin in chemotherapy-naïve patients with diffuse-type adenocarcinoma involving the gastroesophageal junction or stomach.
Introduction
Gastric cancer is a major worldwide health problem and it is the fifth most common malignancy worldwide, with over 600 000 new cases identified worldwide [1] . Despite improvements in diagnosis and treatment, stomach cancer remains the third leading cause of cancer death worldwide, with a median survival of <1 year [1] [2] [3] .
Gastric cancers are categorized based on stage, disease extent, differentiation, location, and gross appearance [4] . Gastric adenocarcinomas are subcategorized as diffuse type, intestinal type, mucinous without signet ring cells, papillary, signet ring cell, or tubular [5, 6] . While age, tumor size, stage, and location are known prognostic factors, histology also is important [5] [6] [7] . However, no histology-based treatment regimen is established. For human epidermal growth factor receptor 2 (HER2)-negative tumor patients, a combination of fluoropyrimidine-and platinum-based therapies are regulatory standards [8] .
S-1, a contemporary oral fluoropyrimidine, was designed to simultaneously improve the antitumor activity of 5-fluorouracil (5-FU) and reduce its toxic effects. S-1 comprises tegafur (a prodrug of 5-FU) and two 5-FU modulators: gimeracil, which inhibits degradation of FU, thereby maintaining high 5-FU concentration, and oteracil potassium, which reduces 5-FU levels in the gut, reducing gastrointestinal toxicity [9] [10] [11] . In the FirstLine Advanced Gastric Cancer Study (FLAGS), the efficacy and safety of S-1/cisplatin (CS), and 5-FU/cisplatin (CF) were assessed in chemotherapy-naïve patients with histologically confirmed advanced gastric cancer. Although no significant difference in overall survival [OS; hazard ratio (HR), 0.92; 95% confidence interval (CI), 0.80-1.05; P ¼ 0.20] was observed, lower rates of grade 3/4 neutropenia, complicated neutropenia, stomatitis, hypokalemia, and treatment-related deaths were reported with CS than CF [12, 13] . Koizumi et al. reported that in the S-1 single-arm phase 2 study, subgroup analysis showed that overall response rate (ORR) in the group of diffuse-type gastric cancer was higher than in the intestinal-type gastric cancer (52% versus 28%) [14] . Also, it was reported that mRNA expression of dihydropyrimidine dehydrogenase (DPD) in diffuse-type gastric cancer was higher than in intestinal type [15] .
A retrospective analysis of FLAGS suggested that survival was improved among patients with advanced diffuse adenocarcinoma (DAC) treated with CS versus CF [11] . Therefore, it was hypothesized that S-1 may contribute to clinical benefit for the patients with diffuse-type gastric cancer rather than 5-FU, because S-1 contains a strong DPD inhibitor, gimeracil. The objective of the Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) was to assess the efficacy and safety of CS versus CF in chemotherapy-naïve patients with DAC of the gastroesophageal junction (GEJ) or stomach. Enrollment was closed early owing to slow accrual, and the trial consequently terminated.
Methods-patients Study design
This was an open-label, international, multicenter, randomized, phase III trial conducted at sites in 20 countries from 14 April 2011 to 15 August 2014. Written informed consent was obtained from all patients, and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation (ICH) Tripartite Guidelines for Good Clinical Practice. An independent data monitoring committee (DMC) monitored the safe conduct of the study. Diffuse-type adenocarcinoma and its variant, signet ring cell adenocarcinoma, were confirmed by blinded central pathology review before randomization.
Patients
Patients aged 18 years with histologically confirmed metastatic DAC involving the GEJ or stomach who were chemotherapy naïve were enrolled. In addition, patients had to have adequate organ function, measurable or nonmeasurable disease, Eastern Cooperative Oncology Performance Status (ECOG-PS) of 0-1, and must not have received any exposure to radiotherapy within 4 weeks or major surgery within 3 weeks of study start. Patients with 10% body weight loss within 3 months before randomization were excluded.
Treatment
Patients were randomized using an interactive voice/web randomization system (2 : 1) to receive CS or CF. In the CS group, S-1 (25 mg/m 2 ) was administered orally twice daily (b.i.d.) on days 1 through 21 followed by a 7-day rest period (days 22-28). One dose of cisplatin (75 mg/m 2 ) was administered intravenously over 1-3 h on day 1 of every 28-day cycle. In the CF group, 5-FU (800 mg/m 2 /24 h) was administered as a continuous infusion over 5 days every 21 days. One dose of cisplatin (80 mg/m 2 ) was administered intravenously over 1-3 h on day 1 of every 21-day cycle before starting the 5-FU infusion. Cisplatin treatment in both groups was limited to 8 cycles.
End points and assessments
Primary end point was OS, defined as time from randomization to date of death. Patients who were alive at cutoff date were censored at date last known to be alive. Secondary end points included progression-free survival (PFS), defined as time from randomization date until date of radiological PD or death; time to treatment failure (TTF), defined as time from randomization date until clinical or radiologic PD date, permanent drug discontinuation, or death; and ORR, defined as Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1, 2009).
Tumor response was assessed by investigators every 8 weeks until evidence of radiologic PD or start of a new antitumor therapy. Survival was assessed every 8 weeks until death or 6 months after randomization of the last enrolled patient.
Histologic criteria for types of adenocarcinoma
Histologic criteria were confirmed by central pathology laboratory before randomization, according to the following criteria:
Histologic criteria for diffuse-type adenocarcinoma included >50% of any of the following: (i) noncohesive single or small nests of cells with little or no gland formation, (ii) carcinoma with solid sheets, tight clusters, and cords of cells, (iii) carcinoma with small cell with absent to minimal intracellular mucin and anaplastic cells with little intracellular mucin, (iv) carcinoma with >50% of individual or combined components described in (i), (ii), and (iii) plus <50% of papillary, tubular, or other components, and (v) carcinoma with predominant diffuse subtype when combination of adenocarcinoma, diffuse type, and signet ring cell subtypes was >50% of tumor.
Histologic criteria for signet ring cell adenocarcinoma included (i) carcinoma with >50% signet ring cells in the cellular component with or without extracellular mucin, (ii) carcinoma with >50% of signet ring cell component plus <50% of papillary, tubular, or other components, and (iii) carcinoma with predominant signet ring cell subtype when combination of adenocarcinoma, diffuse type, and signet ring cell subtypes was >50% of tumor.
Statistical analysis
Enrollment was closed early because of slow accrual, which challenged trial viability. Efficacy parameters were assessed in the intent-to-treat (ITT) population, which comprised all randomized patients. Safety assessments were carried out in the as-treated (AT) population, which comprised patients who initiated the assigned treatment. DIGEST originally was designed to detect, with 80% power, a HR for OS of 0.75 (25% risk reduction) between treatment groups, with a two-sided type 1 error of 0.05, assuming 500 patients were randomized over 30 months of uniform accrual, 42 months of total trial duration, and a target of 427 events (deaths). After enrollment was closed early, a final survival analysis was carried out based on survival data collected up to 6 months after randomization of the last enrolled patient. Because of early study closure, results should be considered exploratory. The difference in OS between treatment groups was assessed using the unstratified log-rank test. Survival was summarized using Kaplan-Meier curves, along with corresponding two-sided 95% CIs for the estimates. Influence of stratification factors and other baseline characteristics were assessed using the stratified logrank test and multivariate Cox regression modeling. PFS and TTF were analyzed using the same methods as for OS. Treatment comparison for ORR was based on Fisher's exact test. Treatment estimates and differences were presented along with the associated 95% CIs using Clopper-Pearson approximation for individual treatment estimates, and normal approximation for difference between groups. Study medication exposure and safety data were summarized descriptively. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 14.0.
A multivariable analysis was carried out to identify potential prognostic and/or predictive factors based on stratification factors [histologic subtype (adenocarcinoma, diffuse type versus signet ring cell adenocarcinoma), metastatic disease (1 site versus 2 or more sites), ECOG status (0 versus 1), and region (North America/Western Europe/Eastern Europe/Rest of World)] and other baseline characteristics. Each factor was separately assessed using a univariate Cox regression model that excluded treatment. Factors significant at the 10% level were considered candidates for the forward selection process, which was used to identify the final subset of relevant prognostic factors. Once the subset was established, treatment was added to the model to estimate the adjusted effect as well as any interactions.
Results

Patient disposition, demographics, and baseline characteristics
At closure of enrollment, 690 and 361 patients had been screened and randomized, respectively: 239 to receive CS and 122 to receive CF (supplementary file S1, available at Annals of Oncology online). Half (51.0%) of the patients were men, and median age was 56.0 years. Most patients had stomach (94.2%) rather than GEJ (5.8%) cancer and > 1 metastasis sites (77.0%). Demographic and baseline characteristics were similar between treatment groups (Table 1) . Efficacy analysis (ITT) population comprised 361 patients (CS, n ¼ 239; CF, n ¼ 122); 359 patients received 1 dose of study medication, including 11 who did not complete their first cycle of treatment at the time of the data cutoff; therefore, the safety (AT) population comprised 348 patients (CS, n ¼ 230; CF, n ¼ 118).
Efficacy
Overall survival. Median survival follow-up time was 18.4 months; 174 (72.8%) patients in the CS group and 90 (73.8%) patients in the CF group had OS events. No statistically significant differences were observed in OS [median OS with CS, 7.5 months (95% CI: 6.7, 9.3); CF, 6.6 months (95% CI: 5.7, 8.1); HR: 0.99 (95% CI: 0.76, 1.28); unstratified log-rank P ¼ 0.9312] ( Figure 1A) . Results for the stratified (as randomized) analysis were similar [HR, 0.90 (95% CI: 0.68, 1.19); stratified log-rank P ¼ 0.4631]. Potential prognostic factors based on the forward selection process were number of metastatic sites, ECOG-PS, race, prior gastrectomy, and peritoneal metastases (Figure 2 ). After adjusting for these prognostic factors in a multivariate analysis, the treatment effect remained similar to that observed in the univariate analysis [HR ¼ 0.97; 95% CI (0.75, 1.25), P ¼ 0.80]. A statistically significant (P ¼ 0.03) interaction was detected between ECOG-PS and treatment; however, the HR 95% CIs for both ECOG-PS subgroups included 1, making the association of ECOG-PS with benefit from CS or CF unclear. Adverse events. Similar percentages of patients in each treatment group had at least one AE, at least one grade 3 AE, and at least one serious AE (SAE).
Abdominal pain, vomiting, and decreased appetite were reported more frequently in the CS group, whereas stomatitis, mucosal inflammation, and asthenia were reported more frequently in the CF group. Fatigue was the only grade 3 nonhematologic AE with 5% difference between treatment groups (CS, 10.4%; CF, 4.2%). Laboratory abnormalities such as increase in alkaline phosphatase or international normalized ratio (INR), hyperuricemia, hyperbilirubinemia, neutropenia, and thrombocytopenia were reported more frequently in the CS group, whereas hypercholesterolemia, increase in creatinine, hypernatremia, and lymphocytopenia were reported more frequently in the CF group. Anemia (CS, 16.1%; CF, 8.0%) and increase in INR (CS, 11.8%; CF, 0%) were the only grade 3 hematologic laboratory abnormalities with 5% difference between treatment groups. The most frequently reported grade 3 laboratory abnormalities (5% in both groups) were hyponatremia (CS, 7.7%; CF, 10.0%), leukocytopenia (CS, 8.5%; CF, 10.0%), neutropenia (CS, 27.3%; CF, 28.3%), and anemia (CS, 16.1%; CF, 8.0%) ( Table 2) .
Discussion
In DIGEST, the efficacy and safety of CS and CF were evaluated in chemotherapy-naïve patients with metastatic DAC involving the stomach or GEJ. Available results demonstrated no significant difference in efficacy and similar safety profiles between both regimens. Furthermore, similar to reports indicating that diffusetype histology results in poor prognosis but is not independently associated with reduced recurrence-free survival or OS [7, 16, 17] , results from DIGEST revealed that histology was not a significant prognostic factor for OS.
Some AEs such as abdominal pain, vomiting, and decreased appetite were reported more frequently in the CS group, whereas stomatitis, mucosal inflammation, and asthenia were reported more frequently in the CF group. Anemia and increase in INR were the only grade 3 hematologic laboratory abnormalities with 5% difference between treatment groups. The most frequently reported grade 3 hematologic laboratory treatmentemergent AEs ( 5% in both groups) were leukocytopenia (CS, 8.5%; CF, 10.0%), neutropenia (CS, 27.3%; CF, 28.3%), and anemia (CS, 16.1%; CF, 8.0%). In FLAGS, a slightly more favorable safety profile was reported for CS [e.g. grade 3 neutropenia (CS, 32.3%; CF, 63.6%)] [12] . Other hematological and nonhematologic toxicities were similar between both treatment groups in FLAGS and the present study.
An obvious limitation of DIGEST was early closure of enrollment, which led to fewer patients than planned being enrolled in the trial and may have affected the study outcome. Nonetheless, neither CS nor CF appeared to be more efficacious in patients with DAC (i.e. histology-specific); however, availability of regimens with or without targeted therapy keeps this perspective open for future research. Furthermore, strategies considering the heterogeneity of this cancer are likely necessary in order to recognize better treatments and to increase the survival benefit of these patients.
Conclusions
In conclusion, the primary end point was not met in DIGEST. Trial enrollment was closed early because of slow accrual, and the trial was subsequently terminated; however, data obtained during accrual and follow-up suggest that first-line chemotherapy with CS and CF is comparable with respect to efficacy and safety in patients with DAC.
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